Backblaze Valuation
Is BLZE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BLZE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BLZE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BLZE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLZE?
Key metric: As BLZE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BLZE's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | US$122.58m |
| Market Cap | US$280.16m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | -14x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BLZE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
CORZ.Q Core Scientific | 0.7x | 31.2% | US$332.9m |
BIGC BigCommerce Holdings | 1.5x | 5.6% | US$473.4m |
TCX Tucows | 0.5x | n/a | US$177.7m |
CXDO Crexendo | 2.4x | 10.4% | US$138.8m |
BLZE Backblaze | 2.3x | 13.4% | US$280.2m |
Price-To-Sales vs Peers: BLZE is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.3x).
Price to Sales Ratio vs Industry
How does BLZE's PS Ratio compare vs other companies in the US IT Industry?
Price-To-Sales vs Industry: BLZE is expensive based on its Price-To-Sales Ratio (2.3x) compared to the US IT industry average (2x).
Price to Sales Ratio vs Fair Ratio
What is BLZE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | 1.9x |
Price-To-Sales vs Fair Ratio: BLZE is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$6.23 | US$12.67 +103.3% | 16.4% | US$16.50 | US$10.00 | n/a | 6 |
| Nov ’25 | US$7.17 | US$12.23 +70.6% | 15.3% | US$15.90 | US$10.00 | n/a | 6 |
| Oct ’25 | US$6.33 | US$12.07 +90.6% | 16.7% | US$15.90 | US$10.00 | n/a | 6 |
| Sep ’25 | US$6.11 | US$12.07 +97.5% | 16.7% | US$15.90 | US$10.00 | n/a | 6 |
| Aug ’25 | US$6.20 | US$12.07 +94.6% | 17.4% | US$15.90 | US$9.00 | n/a | 6 |
| Jul ’25 | US$6.22 | US$12.40 +99.4% | 16.6% | US$15.90 | US$9.00 | n/a | 6 |
| Jun ’25 | US$6.11 | US$13.08 +114.1% | 11.7% | US$15.90 | US$11.50 | n/a | 5 |
| May ’25 | US$9.32 | US$13.77 +47.8% | 16.1% | US$18.00 | US$11.50 | n/a | 7 |
| Apr ’25 | US$10.22 | US$13.49 +32.0% | 17.9% | US$18.00 | US$11.00 | n/a | 7 |
| Mar ’25 | US$11.24 | US$13.49 +20.0% | 17.9% | US$18.00 | US$11.00 | n/a | 7 |
| Feb ’25 | US$8.17 | US$10.80 +32.2% | 29.7% | US$18.00 | US$7.50 | n/a | 7 |
| Jan ’25 | US$7.59 | US$10.80 +42.3% | 29.7% | US$18.00 | US$7.50 | n/a | 7 |
| Dec ’24 | US$7.69 | US$10.80 +40.4% | 29.7% | US$18.00 | US$7.50 | n/a | 7 |
| Nov ’24 | US$5.14 | US$10.67 +107.5% | 34.2% | US$18.00 | US$7.50 | US$7.17 | 6 |
| Oct ’24 | US$5.50 | US$10.67 +93.9% | 34.2% | US$18.00 | US$7.50 | US$6.33 | 6 |
| Sep ’24 | US$6.31 | US$10.59 +67.8% | 32.0% | US$18.00 | US$7.50 | US$6.11 | 7 |
| Aug ’24 | US$5.26 | US$10.23 +94.5% | 32.2% | US$18.00 | US$7.50 | US$6.20 | 7 |
| Jul ’24 | US$4.33 | US$10.23 +136.2% | 32.2% | US$18.00 | US$7.50 | US$6.22 | 7 |
| Jun ’24 | US$4.30 | US$10.23 +137.9% | 32.2% | US$18.00 | US$7.50 | US$6.11 | 7 |
| May ’24 | US$4.12 | US$10.37 +151.7% | 31.8% | US$18.00 | US$7.50 | US$9.32 | 7 |
| Apr ’24 | US$5.05 | US$10.58 +109.6% | 32.6% | US$18.00 | US$8.00 | US$10.22 | 6 |
| Mar ’24 | US$5.55 | US$11.10 +100.0% | 32.0% | US$18.00 | US$8.50 | US$11.24 | 5 |
| Feb ’24 | US$7.15 | US$11.00 +53.8% | 32.9% | US$18.00 | US$8.50 | US$8.17 | 5 |
| Jan ’24 | US$6.15 | US$11.00 +78.9% | 32.9% | US$18.00 | US$8.50 | US$7.59 | 5 |
| Dec ’23 | US$4.48 | US$11.00 +145.5% | 32.9% | US$18.00 | US$8.50 | US$7.69 | 5 |
| Nov ’23 | US$4.78 | US$13.20 +176.2% | 22.3% | US$18.00 | US$9.50 | US$5.14 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Akamai Technologies
US$13.1b
Provides cloud computing, security, and content delivery services in the United States and internationally.
AKAM
US$87.96
7D
-0.9%
1Y
-22.6%
Dye & Durham
CA$1.2b
Provides cloud-based software and technology solutions for law firms, financial service institutions, sole-practitioner law firms, and government organizations in Canada, Australia, South Africa, Ireland, and the United Kingdom.
DYND.F
CA$13.30
7D
8.6%
1Y
39.5%
Capgemini
€26.4b
Engages in the provision of consulting, digital transformation, technology, and engineering services primarily in North America, France, the United Kingdom, Ireland, the rest of Europe, the Asia-Pacific, and Latin America.
CAPM.F
€159.66
7D
-2.8%
1Y
-18.8%